Home / Evaluating the IRA’s Impact on Medicare Part B Biosimilar Reimbursement

WHITE PAPER

Evaluating the IRA’s Impact on Medicare Part B Biosimilar Reimbursement

One less-publicized provision of the Inflation Reduction Act (IRA) enacts a five-year boost in Medicare Part B reimbursement for biosimilar drugs (also known as follow-on biologics or subsequent entry biologics). The biosimilar reimbursement enhancement is meant to overcome financial disincentives to adoption.

Download a free copy of the IRA Biosimilars Outlook 2024 Report

What you’ll learn

The research delves into the IRA’s “small but measurable” impact and offers insights in several key areas, such as:

The relationship between awareness of IRA enhanced Medicare part B reimbursement and utilization of biosimilars at oncology treatment sites

Facility characteristics associated with level of biosimilar utilization

Relationship between eligibility for the IRA biosimilar reimbursement boost and uptake

Drivers of and impediments to biosimilar uptake

Trends in oncology biosimilar uptake and market share

Download the white paper

Submit the form below to download a copy of the IRA Biosimilars Outlook 2024 Report.

About Certara

Certara is dedicated to transforming drug discovery and development for good. We harness the power of biosimulation, advanced analytics, and regulatory expertise to create a future where treatments reach patients faster and more efficiently.

From discovery to market access and commercial, we tailor solutions to meet our clients’ most pressing challenges. Through strategic leadership and advanced predictive technologies, Certara provides comprehensive solutions to optimize drug development processes, reduce risks, and improve outcomes. Our clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.